APX-115

APX-115 (Ewha-18278) is a potent, orally active pan NADPH oxidase (Nox) inhibitor with Ki values of 1.08 μM, 0.57 μM, and 0.63 μM for Nox1, Nox2 and Nox4, respectively. APX-115 can protect ovariectomy-induced osteoporosis and type 2 diabetes-induced renal injury. APX-115 effectively prevents kidney injury such as albuminuria, glomerular hypertrophy, tubular injury, podocyte injury, fibrosis, and inflammation as well as oxidative stress in diabetic mice[1].

Research Areas >> Inflammation/Immunology

Research Areas >> Metabolic Disease

Ki: 1.08 μM (Nox1), 0.57 μM (Nox2) and 0.63 μM (Nox4)[1]

[1]. Kwon G, et al. A novel pan-Nox inhibitor, APX-115, protects kidney injury in streptozotocin-induced diabetic mice: possible role of peroxisomal and mitochondrial biogenesis. Oncotarget. 2017 Jun 16;8(43):74217-74232.